Therapeutic Equivalency Clinical Trial
Official title:
A Single Centre, Two Period Crossover Study to Assess the Bioequivalence of an Oral Azathioprine Suspension 10 mg/mL (Jayempi™) Versus Oral Azathioprine Tablet 50mg (Imurek®) in at Least 30 Healthy Adult Subjects Under Fasting Conditions
A single center, single dose, open-label, randomized, two period crossover study to assess the bioequivalence of an oral azathioprine suspension 10 mg/mL (Jayempi™) versus oral azathioprine tablet 50mg (Imurek®, Aspen Pharma Trading Limited, Dublin, Ireland.) in at least 30 healthy adult subjects under fasting conditions.
This will be a single-dose, open-label, randomised, two-period crossover study with orally administered 1 x 5mL (50 mg) of Jayempi™ Oral Suspension 10mg/mL versus oral azathioprine tablet 50mg (Imurek®, Aspen Pharma Trading Limited, Dublin, Ireland) on two separate occasions conducted under fasting conditions in healthy male and female subjects at a single study centre. The study will comprise: - Thiopurine methyltransferase (TPMT) testing; - Screening period of maximum 28 days - Two treatment periods (each of which will include a PK profile period of 12 hours) separated by a wash-out period of at least 3 calendar days (minimum number of days based on half-life of the analyte) and maximum of 14 calendar days between consecutive administrations of the IMP - A post-study visit 7-10 days after the last dose of the last treatment period of the study. Subjects will be randomly assigned to treatment sequence, prior to the first administration of IMP. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04467346 -
Bioequivalence Study Between Temozolomide Oral Suspension (Ped-TMZ) and Temodal® Capsules
|
Phase 1 | |
| Completed |
NCT00807118 -
Phase 1, Single Dose, Crossover Study to Determine Bioequivalence and to Investigate Food Effect
|
Phase 1 | |
| Withdrawn |
NCT01405170 -
A Bioequivalence Study Comparing Methylprednisolone Suspension to Methylprednisolone Tablets Under Fed Conditions
|
Phase 1 | |
| Completed |
NCT04885660 -
Bioequivalence Evaluation of Two Fixed-dose Combination of Lisinopril 10mg/Levamlodipine Besylate 5mg in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT05786339 -
Bioequivalence Study of Two Irbesartan in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT00709189 -
Bioequivalence Study of the Oral Contraceptive Tablet Containing Norgestimate (NGM)/Ethinyl Estradiol (EE) With or Without Folic Acid in Healthy Women.
|
Phase 1 | |
| Completed |
NCT00658541 -
Fed Bioequivalence Study of Zolpidem Tartrate Tablets and Ambien® Tablets
|
Phase 1 | |
| Completed |
NCT00685165 -
Fasted Bioequivalence Study of Primidone Tablets and Mysoline Tablets
|
Phase 1 | |
| Completed |
NCT00997789 -
Bioequivalence of Rebamipide in Korean
|
N/A | |
| Completed |
NCT00684762 -
Fasted Bioavailability Study of Cilostazol Tablets, 100 mg
|
Phase 1 | |
| Recruiting |
NCT04814589 -
Bioequivalence of Ezetimibe Tablets in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT03631316 -
Pharmacokinetic Parameters of Innovative Valganciclovir Versus Generic Valganciclovir
|
N/A | |
| Recruiting |
NCT04438720 -
Bioequivalence of Extended Release Nifedipine Tablets in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT01359163 -
A Study To Determine Bioequivalence Between The Commercial Femulen Tablets And A Reformulation Of Femulen Tablets In Healthy Female Subjects
|
Phase 1 | |
| Completed |
NCT00650221 -
Fasting Bioequivalence Study of Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Normal Healthy Subjects
|
Phase 1 | |
| Completed |
NCT00648544 -
Fed, Bioequivalence Study of Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Subjects
|
Phase 1 | |
| Completed |
NCT05225974 -
A Randomized Phase 1 Study of Liralutide Injection in Healthy Chinese Subjects
|
Phase 1 | |
| Withdrawn |
NCT01405131 -
A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets
|
Phase 1 | |
| Withdrawn |
NCT01405157 -
A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets Under Fasting Conditions
|
Phase 1 | |
| Completed |
NCT05282940 -
Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product
|
Phase 1 |